Profile data is unavailable for this security.
About the company
Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.
- Revenue in GBP (TTM)3.10m
- Net income in GBP-6.51m
- Incorporated2001
- Employees12.00
- LocationFutura Medical PLC40 Occam RoadGUILDFORD GU2 7YGUnited KingdomGBR
- Phone+44 14 8368 5670Fax+44 14 8368 5671
- Websitehttps://www.futuramedical.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
Oxford Biodynamics PLC | 617.00k | -11.11m |
Incanthera PLC | 0.00 | -1.48m |
Arecor Therapeutics PLC | 4.57m | -8.55m |
Sareum Holdings Plc | 0.00 | -4.26m |
Poolbeg Pharma PLC | 0.00 | -3.93m |
Faron Pharmaceuticals Oy | 0.00 | -26.22m |
Scancell Holdings Plc | 0.00 | -11.32m |
Futura Medical PLC | 3.10m | -6.51m |
hVIVO PLC | 56.04m | 16.12m |
Avacta Group Plc | 23.25m | -24.95m |
4Basebio PLC | 506.00k | -7.67m |
Allergy Therapeutics plc | 53.26m | -50.22m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Lombard Odier Asset Management (Europe) Ltd.as of 16 Jun 2023 | 68.25m | 22.64% |
UBS Asset Management (UK) Ltd.as of 01 Apr 2024 | 33.46m | 11.10% |
Janus Henderson Investors UK Ltd.as of 01 Apr 2024 | 26.56m | 8.81% |
Lombard Odier Asset Management (USA) Corp.as of 01 Apr 2024 | 10.71m | 3.55% |
Chelverton Asset Management Ltd.as of 31 Mar 2023 | 8.81m | 2.92% |
Hargreaves Lansdown Asset Management Ltd.as of 01 Apr 2024 | 8.25m | 2.74% |
Atlantis Investment Management Ltd. /Hong Kong/as of 21 Apr 2021 | 7.94m | 2.63% |
Unicorn Asset Management Ltd.as of 01 Apr 2024 | 5.75m | 1.91% |
Maitland Asset Management (Pty) Ltd.as of 01 Apr 2024 | 4.84m | 1.60% |
Credit Suisse Asset Management (Schweiz) AGas of 01 Apr 2024 | 4.47m | 1.48% |